Arrowhead Pharmaceuticals

Vanguard Portfolio Management (NASDAQ: ARWR) reports 5.19% stake in Arrowhead Stock Titan

A Look At Arrowhead Pharmaceuticals (ARWR) Valuation After EMA CHMP Backs REDEMPLO For FCS simplywall.st

ARWR rallies 7% this week as Europe edges closer to Redemplo approval amid analyst optimism MSN

ARWR Stock Price, Quote & Chart | ARROWHEAD PHARMACEUTICALS IN (NASDAQ:ARWR) ChartMill

This Biotech Stock Is Up 460% Over the Past Year. Why Analysts See It Rising Higher. Barron's

Arrowhead Pharmaceuticals to Webcast Fiscal 2026 Second Quarter Results Business Wire

Assessing Arrowhead Pharmaceuticals (ARWR) Valuation After A Cooling Share Price And Strong Long-Term Returns Yahoo Finance

Arrowhead Pharmaceuticals Announces Proposed Offerings of Convertible Senior Notes and Common Stock Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the U.S. Food and Drug Administration (FDA) has approved REDEMPLO (plozasiran), a small interfering RNA (siRNA) medicine, as an adju

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on November 25, 2025, at 4:30 p.m. ET to discuss its financial results for the 2025 fisca

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: American Heart Association (AHA) Scientific Sessions 2025 – Novemb

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on October 24, 2025, the Company’s Board of Directors approved “induc

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that a global licensing and collaboration agreement with Novartis, previously announced on September 2, 2025, has now closed. Closing of

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has filed a request for regulatory clearance to initiate a Phase 1/2a clinical trial of ARO-DIMER-PA, the company’s investigation

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that yesterday it filed a Complaint for Declaratory Judgment in the United States District Court for the District of Delaware against Ion

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has filed a request for regulatory clearance to initiate a Phase 1/2a clinical trial of ARO-MAPT, the company’s investigational R